Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral NNC0113-0987 dosing conditions in healthy males
NCT02094521Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2014
- Primary completion
- Jul 2014
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoint: Area under the NNC0113-0987 plasma concentration time curve. Started Mar 2014; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02094521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02094521.